186 related articles for article (PubMed ID: 23197369)
1. Cost effectiveness of full coverage of the medical management of smoking cessation in France.
Chevreul K; Cadier B; Durand-Zaleski I; Chan E; Thomas D
Tob Control; 2014 May; 23(3):223-30. PubMed ID: 23197369
[TBL] [Abstract][Full Text] [Related]
2. Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases.
Cadier B; Durand-Zaleski I; Thomas D; Chevreul K
PLoS One; 2016; 11(2):e0148750. PubMed ID: 26909802
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of call-back counselling for smoking cessation.
Lal A; Mihalopoulos C; Wallace A; Vos T
Tob Control; 2014 Sep; 23(5):437-42. PubMed ID: 23748188
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a microsimulation economic model to evaluate the disease burden associated with smoking and the cost-effectiveness of tobacco control interventions in Latin America.
Pichon-Riviere A; Augustovski F; Bardach A; Colantonio L;
Value Health; 2011; 14(5 Suppl 1):S51-9. PubMed ID: 21839900
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison.
Cornuz J; Gilbert A; Pinget C; McDonald P; Slama K; Salto E; Paccaud F
Tob Control; 2006 Jun; 15(3):152-9. PubMed ID: 16728744
[TBL] [Abstract][Full Text] [Related]
7. The carbon footprint of behavioural support services for smoking cessation.
Smith AJ; Tennison I; Roberts I; Cairns J; Free C
Tob Control; 2013 Sep; 22(5):302-7. PubMed ID: 23481905
[TBL] [Abstract][Full Text] [Related]
8. A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand.
Thavorn K; Chaiyakunapruk N
Tob Control; 2008 Jun; 17(3):177-82. PubMed ID: 18285385
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study.
Feenstra TL; Hamberg-van Reenen HH; Hoogenveen RT; Rutten-van Mölken MP
Value Health; 2005; 8(3):178-90. PubMed ID: 15877590
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.
Linden K; Jormanainen V; Linna M; Sintonen H; Wilson K; Kotomäki T
Curr Med Res Opin; 2010 Mar; 26(3):549-60. PubMed ID: 20050814
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
Lutz MA; Lovato P; Cuesta G
Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
[TBL] [Abstract][Full Text] [Related]
12. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
Schädlich PK; Brecht JG; Rangoonwala B; Huppertz E
Pharmacoeconomics; 2004; 22(15):955-73. PubMed ID: 15449961
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of treating nicotine dependence: the Mayo Clinic experience.
Croghan IT; Offord KP; Evans RW; Schmidt S; Gomez-Dahl LC; Schroeder DR; Patten CA; Hurt RD
Mayo Clin Proc; 1997 Oct; 72(10):917-24. PubMed ID: 9379693
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analyses of health promotion programs: a case study of smoking prevention and cessation among Dutch students.
Vijgen SM; van Baal PH; Hoogenveen RT; de Wit GA; Feenstra TL
Health Educ Res; 2008 Apr; 23(2):310-8. PubMed ID: 17675649
[TBL] [Abstract][Full Text] [Related]
16. Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia.
Bertram MY; Lim SS; Wallace AL; Vos T
Tob Control; 2007 Aug; 16(4):255-60. PubMed ID: 17652241
[TBL] [Abstract][Full Text] [Related]
17. The potential of smoking cessation programmes and a smoking ban in public places: comparing gain in life expectancy and cost effectiveness.
Højgaard B; Olsen KR; Pisinger C; Tønnesen H; Gyrd-Hansen D
Scand J Public Health; 2011 Dec; 39(8):785-96. PubMed ID: 21976052
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of intensive smoking cessation therapy among patients with small abdominal aortic aneurysms.
Mani K; Wanhainen A; Lundkvist J; Lindström D
J Vasc Surg; 2011 Sep; 54(3):628-36. PubMed ID: 21620630
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of a European primary-care physician training in smoking cessation counseling.
Pinget C; Martin E; Wasserfallen JB; Humair JP; Cornuz J
Eur J Cardiovasc Prev Rehabil; 2007 Jun; 14(3):451-5. PubMed ID: 17568248
[TBL] [Abstract][Full Text] [Related]
20. Evaluating a collaborative smoking cessation intervention in primary care (ENTER): study protocol for a cluster-randomized controlled trial.
Härter M; Bartsch AL; Egger N; König HH; Kriston L; Schulz H; Tiemann M; Brütt AL; Buchholz A
Trials; 2015 Oct; 16():447. PubMed ID: 26452466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]